Eknath D. Ahire

Dr. Eknath D. Ahire

METs, Institute of Pharmacy, BKC, Adgoan, Nashik, MH, India, Nashik, India
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
STShreya Thakkar
Shreya Thakkar
MDMahesh Darshanwad
Mahesh Darshanwad
MMmanju misra
manju misra
Advancements in in silico techniques of lead molecule selection have resulted in the failure of around 70% of new chemical entities (NCEs). Some of these molecules are getting rejected at final developmental stage resulting in wastage of money and resources. Unfavourable physicochemical properties affect ADME profile of any efficacious and potent molecule, which may ultimately lead to killing of NCE at final stage. Numerous techniques are being explored including nanocrystals for solubility enhancement purposes. Nanocrystals are the most successful and the ones which had a shorter gap between invention and subsequent commercialization of the first marketed product. Several nanocrystal-based products are commercially available and there is a paradigm shift in using approach from simply being solubility enhancement technique to more novel and specific applications. Some other aspects in relation to parenteral nanosuspensions are concentrations of surfactant to be used, scalability and in vivo fate. At present, there exists a wide gap due to poor understanding of these critical factors, which we have tried to address in this review. This review will focus on parenteral nanosuspensions, covering varied aspects especially stabilizers used, GRAS (Generally Recognized as Safe) status of stabilizers, scalability challenges, issues of physical and chemical stability, solidification techniques to combat stability problems and in vivo fate.

30 January 2024 in Smart Medicine
Verified
Journal Article
Open access
ARAmit Kumar Rajora
Amit Kumar Rajora
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
ARAmit Kumar Rajora
Amit Kumar Rajora
SSSukhvir Singh
Sukhvir Singh
JBJaydeep Bhattacharya
Jaydeep Bhattacharya
Hongbo ZhangHongbo Zhang
Hongbo Zhang
Cancer remains a major global health threat necessitating the multipronged approaches for its prevention and management. Traditional approaches in the form of chemotherapy, surgery, and radiotherapy are often encountered with poor patient outcomes evidenced by high mortality and morbidity, compelling the need for precision medicine for cancer patients to enable personalized and targeted cancer treatment. There has been an emergence of smart multimodal theranostic nanoformulation for triple combination cancer therapy in the last few years, which dramatically enhances the overall safety of the nanoformulation for in vivo and potential clinical applications with minimal toxicity. However, it is imperative to gain insight into the limitations of this system in terms of clinical translation, cost‐effectiveness, accessibility, and multidisciplinary collaboration. This review paper aims to highlight and compare the impact of the recent theranostic nanoformulations of triple therapeutics in a single nanocarrier for effective management of cancer and provide a new dimension for diagnostic and treatment simultaneously.

4 May 2026 in National Academy Science Letters
Verified
Journal Article
Closed access
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
SKSmita Prakash Kakad
Smita Prakash Kakad
MPMayuri Pawar
Mayuri Pawar
PGPrerna Ghatol
Prerna Ghatol
SPSneha Palaskar
Sneha Palaskar
SKSanjay J. Kshirsagar
Sanjay J. Kshirsagar

12 December 2023 in Materials Today: Proceedings
Verified
Journal Article
Closed access
RSRahul R. Sable
Rahul R. Sable
DTDivya G. Thite
Divya G. Thite
PUPavan B. Udavant
Pavan B. Udavant
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
SKShubham J. Khairnar
Shubham J. Khairnar

1 July 2023 in Materials Today: Proceedings
Verified
Journal Article
Closed access
SASapana P. Ahirrao
Sapana P. Ahirrao
DBDeepak S. Bhambere
Deepak S. Bhambere
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
NDNeelam L. Dashputre
Neelam L. Dashputre
SKSmita P. Kakad
Smita P. Kakad
ULUmesh D. Laddha
Umesh D. Laddha

30 May 2025 in Applied Nano
Verified
Journal Article
Open access
PDF file
Eknath D. AhireEknath D. Ahire
Eknath D. Ahire
SSavaliya Namrtaben vinodbhai Vinodbhai
Savaliya Namrtaben vinodbhai Vinodbhai
KMKALARAV VINODBHAI MAKWANA
KALARAV VINODBHAI MAKWANA
Sagar SalaveSagar Salave
Sagar Salave
MBMandeep Kaur Banth
Mandeep Kaur Banth
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Protein-bound nano-injectable solutions represent a cutting-edge advancement in nanomedicine, offering a versatile platform for precise and controlled drug delivery. By leveraging the biocompatibility and functional versatility of proteins such as albumin, gelatin, and casein, these nano systems enhance drug solubility, prolong circulation time, and improve site-specific targeting, which are particularly beneficial in cancer and inflammatory diseases. This review provides a comprehensive overview of their formulation strategies, physicochemical characteristics, and biological behavior. Emphasis is placed on therapeutic applications, regulatory considerations, fabrication techniques, and the underlying mechanisms of drug–protein interactions. This review also highlights improved pharmacokinetics and reduced systemic toxicity, while also critically addressing challenges like immunogenicity, protein instability, and production scalability. Recent FDA-approved formulations and emerging innovations in precision medicine and theranostics underscore the transformative potential of protein-based nanosuspensions in next-generation drug delivery systems.